Proactive Investors UKFusion IP overcomes European hurdleYorkshire PostUNIVERSITY research incubator Fusion IP said today its portfolio company Diurnal had overome a European regulatory hurdle after receiving approval for a paediatric version of hydroc…
Proactive Investors UK |
Fusion IP’s Diurnal gets European boost for infant hydrocortisone treatment
Proactive Investors UK Diurnal, one of Fusion IP’s (LON:FIP) portfolio of university spin-off companies, has cleared a major regulatory hurdel in Europe for Infacort, its hydrocortisone treatment for children. The European Medicines Agency (EMA) has approved a Paediatric … Fusion IP overcomes European hurdleYorkshire Post Diurnal paediatric investigation plan gets EMA approvalStock Market Wire University spin-out overcomes major hurdleThe Business Desk (registration) |
|
University spin-out overcomes major hurdle
The Business Desk (registration) This is for a new formulation of hydrocortisone – Infacort. Diurnal is developing a novel approach to drug delivery that will help patients suffering from reduced levels of the key hormone cortisol (……for the full story register now for free or … |
RECORD-3: Sunitinib Still Standard First-Line Treatment in Metastatic RCCCancer NetworkThe mTOR inhibitor everolimus failed to prove progression-free survival noninferiority compared with the VEGF-targeting tyrosine kinase inhibitor sunitinib when give…
|
Hydrocortisone for BPD: No effect on brain growth
ModernMedicine There’s good news for premature infants with bronchopulmonary dysplasia (BPD): treatment with hydrocortisone does not seem to adversely effect brain growth, meaning that it may provide a safer alternative to dexamethasone. Bronchopulmonary dysplasia … |
|
BOLERO-3: Everolimus tweaks trastuzumab-resistant metastatic breast cancer
Ob.Gyn. News Digital Network CHICAGO – Adding the mTOR inhibitor everolimus to trastuzumab and vinorelbine reduced the risk of progression by 22% in women with trastuzumab-resistant, HER2-positive breast cancer that progressed after taxane therapy. This translated into a gain of … |
BOLERO-2 Trial: Everolimus in Metastatic Breast CancerOncLiveInitially, research into the mTOR inhibitor everolimus was undertaken in the neoadjuvant setting, looking for a potential biomarker, explains Rugo. In this trial, a great deal of information …
|
Body Fat, Insulin May Be Key in Adrenal Disorder
MedPage Today “Increased adiposity, insulin resistance, and the use of combination glucocorticoid therapy with prednisolone and dexamethasone are associated with impaired QoL in adults with CAH independently of mutation severity,” the authors concluded. “However … |
Systemic JIA patients successfully discontinued corticosteroids through …HealioSuccessful tapering of corticosteroid use was achieved for almost half the patients with systemic juvenile idiopathic arthritis through canakinumab therapy in a study pres…
Canakinumab allows discontinuation of corticosteroids in patients with SJIAScience CodexMadrid, Spain, 13 June 2013: Study findings first presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate the effi…